Arcutis Biotherapeutics, Inc.
Company Stats
- Market Cap
- $3.3B
- as of Sep 30, 2026
- Enterprise Value
- $3.4B
- Shares Outstanding
- 125.7M
- Free Float
- 79.2%
Income Statement
- Revenue
- $376.1M
- Operating Income
- -$12.2M
- Net Income
- -$16.1M
- EBITDA
- -$11.5M
- Revenue Growth, 3Y
- 367.3%
- FCF Margin, 3Y Avg
- -158.0%
- FCF Margin, Worst Year
- -415.2%
Cash Flow
- Free Cash Flow
- -$6.3M
- FCF Yield
- -0.2%
- Owner FCF Yield
- -1.4%
Balance Sheet
- Cash & Equivalents
- $42.9M
- Total Debt
- $100.0M
- Net Debt
- $57.1M
Returns & Capital
- SBC, 3Y Avg
- $40.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $376.1M | -$6.3M | -1.7% |
| FY2024 | $196.5M | -$112.3M | -57.1% |
| FY2023 | $59.6M | -$247.5M | -415.2% |
| FY2022 | $3.7M | -$258.0M | -7000.8% |
| FY2021 | $0 | -$175.6M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back